Top Markets
#1 Akedo Akedo +70.44%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.33%
#4 Cross Cross +45.97%
#5 Velvet Velvet +34.78%
#6 Black Phoenix Black Phoenix +34.22%
#7 OVERTAKE OVERTAKE +21.57%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
#9 Movement Movement +13.74%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +13.14%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BLCM
Classifica tra le azioni #38877
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage... Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Prezzo delle azioni
$0.07475
Ultima sincronizzazione: 2024-03-04
Capitalizzazione di mercato
$755.60K
Variazione (1 giorno)
-6.68%
Variazione (1 anno)
0.00%
Paese
US
Scambia Bellicum Pharmaceuticals, Inc. (BLCM)

Categoria

Healthcare
Ricavi di Bellicum Pharmaceuticals, Inc. (BLCM)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Bellicum Pharmaceuticals, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Bellicum Pharmaceuticals, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE